Paratek Pharmaceuticals (NASDAQ: PRTK)
Some price data may be temporarily unavailable.
Paratek Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Paratek Pharmaceuticals Company Info
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
News & Analysis
Why Paratek Pharmaceuticals Stock Is Sinking Today
The company reduced its 2021 revenue outlook.
Why Paratek Pharmaceuticals Crushed the Market Today
The company gets off to a roaring start in June with an important FDA nod.
Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today
Find out which of these companies is looking for a buyer.
Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today
The pharma company announced a debt offering that has Wall Street scrambling.
Why Paratek Pharmaceuticals Is Sinking Today
Shares dive after the antibiotic drug developer announces the pricing details of a secondary common stock offering.
3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis
Paratek Corp., Nabriva Therapeutics, and Cempra all appear on course to bring new antibiotics to market soon. But which could be the best bet for your portfolio now?
Why Nabriva Therapeutics Shares Are Falling Today
The roller-coaster ride continues for this clinical-stage biotech's stock.
Why Nabriva Therapeutics PLC Is Skyrocketing
Shares soar after the company reports upbeat data from a pivotal clinical trial.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.